I-MAB (IMAB) Price & Analysis

Compare

386 Followers

IMAB Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.60 - $5.90

Previous CloseN/A

Volume876.01K

Average Volume (3M)3.26M

Market Cap

$410.22M

Enterprise Value$35.58M

Total Cash (Recent Filing)$184.39M

Total Debt (Recent Filing)$3.78M

Price to Earnings (P/E)―

Beta1.83

Next Earnings

Nov 13, 2025

EPS Estimate

-0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding81,660,350

10 Day Avg. Volume2,637,410

30 Day Avg. Volume3,257,483

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.09

Enterprise Value/Revenue8.91

Enterprise Value/Gross Profit8.91

Enterprise Value/Ebitda-0.12

Forecast

1Y Price Target

$7.00

Price Target Upside55.56% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Efficacy And Response RatesThe release of Phase 1b dose-escalation data for givastomig demonstrated an objective response rate of 83 percent, with deepened responses over time and a six-month progression-free survival rate of 82 percent.

Financial StabilityThe August 2025 financing extends cash runway into the fourth quarter of 2028, allowing I-Mab to carry givastomig through a randomized Phase 2 trial.

Market PotentialGivastomig offers industry-leading Claudin 18.2 patient coverage, enabled by a uniquely permissive ≥1% expression threshold, compared to zolbetuximab's ≥75% cutoff.

Bears Say

Comparative EfficacyAs the data matures, it will be important for giva to demonstrate a mPFS at least as long as the one seen for zolbi + chemo.

Safety ConcernsGrade ≥3 neutropenia was attributed to chemo and likely driven by a temporary restriction on the use of growth factors.

I-MAB News

I-Mab appoints Lenz, Liu to board of directors, forms R&D Committee

I-Mab (IMAB) announced the appointment of independent directors, Dr. Robert Lenz and Ms. Xin Liu, to its Board...

4d ago

IMAB

I-Mab price target raised to $6 from $5 at Needham

Needham raised the firm’s price target on I-Mab (IMAB) to $6 from $5 and keeps a Buy rating...

8d ago

IMAB

I-Mab reports Q2 EPS (3c), consensus (5c)

“The first half of 2025 has been transformative for I-Mab (IMAB),” said Sean Fu, PhD, Chief Executive Officer...

9d ago

IMAB

I-Mab sees cash runway through 4Q28

As of June 30, 2025, the Company had cash and cash equivalents, and short-term investments of $165.6 million....

9d ago

IMAB

I MAB (ADS) options imply 11.8% move in share price post-earnings

Pre-earnings options volume in I MAB (ADS) is normal with calls leading puts 11:2. Implied volatility suggests the...

10d ago

IMAB

I-Mab completes enrollment in Phase 1b dose expansion study for givastomig

I-Mab (IMAB) announced that enrollment in the planned Phase 1b dose expansion cohorts evaluating givastomig, a bispecific Claudin...

18d ago

IMAB

3 Penny Stocks to Watch Now, 8/5/25

Tenon Medical, BioXcel Therapeutics, and I-Mab are the 3 Penny Stocks to watch on August 5, 2025, based on TipRanks’ Penny...

24d ago

BTAI

IMAB

Everest Medicines announces strategic equity investment in I-Mab

Everest Medicines announced that it has made a strategic equity investment in I-Mab (IMAB). Rogers Yongqing Luo, CEO...

28d ago

IMAB

I-Mab prices 33.3M ADSs at $1.95 in underwritten offering

I-Mab (IMAB) announced the pricing of an underwritten offering in the United States of 33,333,334 American Depositary Shares...

28d ago

IMAB

I-Mab Strengthens Leadership with New Board Appointments and R&D Committee Formation

I-MAB ( ($IMAB) ) has provided an update. On August 22, 2025, I-Mab announced the appointment of Dr....

4d ago

IMAB

I-Mab’s Q2 2025: Clinical Progress and Financial Strength

I-Mab Adr ( ($IMAB) ) has released its Q2 earnings. Here is a breakdown of the information I-Mab...

8d ago

IMAB

I-MAB’s Positive Outlook: Buy Rating Backed by Financial Stability and Promising Clinical Developments

Analyst Gil Blum of Needham maintained a Buy rating on I-MAB, boosting the price target to $6.00. Gil...

8d ago

IMAB

I-Mab Reports Strong Financials and Clinical Progress in August 2025

I-MAB ( ($IMAB) ) just unveiled an update. On August 20, 2025, I-Mab announced its financial results for...

9d ago

IMAB

I-Mab Completes Enrollment in Phase 1b Study for Givastomig in Gastric Cancer

I-MAB ( ($IMAB) ) has provided an announcement. On August 11, 2025, I-Mab announced the completion of enrollment...

18d ago

IMAB

IMAB FAQ

What was I-MAB’s price range in the past 12 months?

I-MAB lowest stock price was $0.59 and its highest was $5.90 in the past 12 months.

What is I-MAB’s market cap?

I-MAB’s market cap is $410.22M.

When is I-MAB’s upcoming earnings report date?

I-MAB’s upcoming earnings report date is Nov 13, 2025 which is in 76 days.

How were I-MAB’s earnings last quarter?

I-MAB released its earnings results on Aug 20, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.054 by $0.024.

Is I-MAB overvalued?

According to Wall Street analysts I-MAB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does I-MAB pay dividends?

I-MAB does not currently pay dividends.

What is I-MAB’s EPS estimate?

I-MAB’s EPS estimate is -0.04.

How many shares outstanding does I-MAB have?

I-MAB has 81,660,350 shares outstanding.

What happened to I-MAB’s price movement after its last earnings report?

I-MAB reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.054. Following the earnings report the stock price went up 7.363%.

Which hedge fund is a major shareholder of I-MAB?

Currently, no hedge funds are holding shares in IMAB

I-MAB Stock Smart Score

Outperform

Fundamentals

Return on Equity

-22.37%

Trailing 12-Months

Asset Growth

-42.27%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

I-MAB

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

I-MAB (IMAB) Earnings & Revenues

Historic Earnings Reports

IMAB Stock 12 Month Forecast

Average Price Target

$7.00

▲(55.56% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","-1":"-$1","1.5":"$1.5","6.5":"$6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.62,3.033846153846154,3.447692307692308,3.8615384615384616,4.275384615384615,4.68923076923077,5.103076923076923,5.516923076923077,5.930769230769231,6.344615384615385,6.758461538461539,7.172307692307693,7.586153846153846,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.62,2.956923076923077,3.293846153846154,3.630769230769231,3.9676923076923076,4.304615384615385,4.641538461538461,4.978461538461539,5.315384615384616,5.6523076923076925,5.989230769230769,6.326153846153846,6.663076923076924,{"y":7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.62,2.88,3.14,3.4000000000000004,3.66,3.92,4.18,4.44,4.7,4.96,5.220000000000001,5.48,5.74,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.82,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.79,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.85,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.79,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.62,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >